Key result
Right minithoracotomy for redo mitral valve procedures demonstrated a 30-day mortality of 4% compared to 11% in the overall cohort, with no postoperative neurological complications.
Why the study?
A minimally invasive approach via thoracotomy is an alternative in challenging redo cardiac procedures, motivating an evaluation of early postoperative experience with right minithoracotomy versus resternotomy in redo mitral valve surgery.
Does a right minithoracotomy improve early postoperative outcomes compared to resternotomy in patients undergoing a redo mitral valve procedure?
Cohort (n=53)
Does a right minithoracotomy improve early postoperative outcomes compared to resternotomy in patients undergoing a redo mitral valve procedure?
A minimally invasive right minithoracotomy is a safe alternative to resternotomy for redo mitral valve procedures in selected patients, demonstrating low mortality and reduced blood loss.
Right minithoracotomy appears feasible for redo mitral reoperations; leaves open need for larger comparative trials.
OBJECTIVES: A minimally invasive approach via a thoracotomy is an alternative in challenging redo cardiac procedures. Our goal was to present our early postoperative experience with minimally invasive cardiac surgery via a right minithoracotomy (minimally invasive) and resternotomy in patients undergoing a mitral valve procedure as a reoperation. METHODS: From 2017 until 2020, reoperation of the mitral valve was performed through a right-sided minithoracotomy in 27 patients and via a resternotomy in 26 patients. Patients with femoral vessels suitable for cannulation underwent a minimally invasive technique. Patients requiring concomitant procedures regarding the aortic valve were operated on via a resternotomy. RESULTS: The mean age was 66 ± 12 years in the minimally invasive group and 65 ± 12 years in the whole cohort. The average Society of Thoracic Surgeons score was 11 ± 10% in the minimally invasive group and 13 ± 9% in all patients. The majority of the patients underwent reoperation because of severe mitral valve insufficiency (48% and 55%, respectively). The mean time to reoperation was 7 ± 9 years (minimally invasive group). The 30-day mortality was 4% in the minimally invasive group and 11% in the whole cohort. The blood loss was 566 ± 359 ml in the minimally invasive group and 793 ± 410 ml totally. There were no postoperative neurological complications in the minimally invasive group and 1 (2%) in the whole cohort. Postoperative echocardiography revealed competent mitral valve/prosthesis function in all patients. CONCLUSIONS: A minimally invasive approach for a mitral valve reoperation in selected patients is a safe alternative to resternotomy with a low transfusion requirement. Both surgical techniques are associated with good postoperative outcomes.
No takes yet. Share an insight, caveat, or question.
Monsefi et al. (2021) conducted a cohort in Redo mitral valve procedure (n=53). Right minithoracotomy vs. Resternotomy was evaluated on 30-day mortality. Right minithoracotomy for redo mitral valve procedures demonstrated a 30-day mortality of 4% compared to 11% in the overall cohort, with no postoperative neurological complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: